Radiant Pharmaceuticals (NYSE AMEX: RPC) CEO Interview

This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.

Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!

Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here

Get an Equifax 3-in-1 Credit Report Now!

Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why TradeKing.com was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).

Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition!

LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.

Get FICO Score Watch Now!

Free Quicken Online automatically categorizes your expenses.

Click here to get access to powerful investing tools only available at Investor’s Business Daily.

Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here

Radiant Pharmaceuticals
Douglass MacClellan, Chairman & CEO

Radient Pharmaceuticals Corporation, formerly AMDL, Inc., is a vertically integrated specialty pharmaceutical company with three distinct business divisions that include In-Vitro diagnostics, China-based pharmaceutical manufacturing and distribution and cancer therapeutics. These business units focus on the development, manufacturing, distribution and sales of medical diagnostic products, generic pharmaceuticals, nutritional supplements, and cosmetics in the United States, China, Korea, Taiwan and other markets. The Company also has been engaged in the commercial development of and the obtaining of various governmental regulatory approvals for the marketing of its diagnostic tumor-marker test kit (DR-70) to detect the presence of multiple types of cancer. The Company operates in China through its wholly owned subsidiary, Jade Pharmaceutical Inc. (JPI).

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.